💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to international markets. The Company manufactures a diverse range of antacid molecules.…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, slow-growing business, fairly priced.
PAR DRUGS AND CHEM LTD is scored on the general / industrial framework. It keeps a healthy 12.2% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.25× reported profit. It throws off free cash worth 10.6% of its market value — a strong free-cash yield.
Over the last 3 years revenue compounded at 4%/yr and profit at 5%/yr. Book value itself has compounded 16%/yr — the hallmark of a genuine compounder. Return on equity is a modest 10.9%. In the latest quarter profit fell 44% versus the prior quarter.
At 10× earnings, the stock sits at the 43rd percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price asks for only ~-0%/yr growth over a decade — undemanding expectations. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 10.32 | 2.98 | worse |
| P/B | 1.12 | 2.69 | better |
| EV/EBITDA | 4.82 | 10.45 | better |
| ROE | 10.89 | — | — |
| ROCE | 14.45 | 69.92 | worse |
| ROA | 9.36 | 54.03 | worse |
| Quick Ratio | 4.29 | 2.26 | better |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
4% CAGR — growing but slowly.
Operating margins have been stable around 16% — no major structural shift.
ROE at 12% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 5% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.3× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 15% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (38% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 18% above earlier ones.
Profit fell 44% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (16% → 10%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 73.4% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.